Precigen Inc (NASDAQ:PGEN)

2.45
Delayed Data
As of Jan 27
 -0.26 / -9.59%
Today’s Change
2.44
Today|||52-Week Range
9.89
-33.96%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$580.9M

Company Description

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the following segments: Biopharmaceuticals, Exemplar, and Trans Ova. The Biopharmaceuticals segment is involved in advancing the next generation of gene and cell therapies using precision technology to target urgent and intractable diseases in immuno-oncology, autoimmune disorders, and infectious diseases. It also engages in pioneering a proprietary class of microbe-based biopharmaceuticals that enable expression and local delivery of disease-modifying therapeutics. The Exemplar segment is focused on developing research models and services for healthcare research applications. The Trans Ova segment provides bovine reproductive technologies. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Contact Information

Precigen, Inc.
20374 Seneca Meadows Parkway
Germantown Maryland 20876
P:(301) 556-9900
Investor Relations:

Employees

Shareholders

Other institutional9.78%
Individual stakeholders52.65%
Mutual fund holders17.51%

Top Executives

Helen SabzevariPresident, Chief Executive Officer & Director
Rutul R. ShahHead-Operations & Portfolio
Harry ThomasianChief Financial Officer
Thomas David ReedChief Science Officer
Douglas E. BroughHead-Research